查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370946

病毒載體生產 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按載體類型、工作流程、按應用、最終用戶、地區、競爭細分

Viral Vector Production - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Vector Type, By Workflow, By Application, By End User, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年全球病毒載體生產市場估值為52.2億美元，預計在預測期內將大幅成長，預計年複合成長率（CAGR）為14.21%，預計到2028年將達到115.4億美元。載體生產需要創建和製造改良病毒（稱為病毒載體），用於將遺傳物質傳遞到目標細胞中，用於多種醫學和生物技術應用。這些病毒載體是基因治療和基因編輯等先進治療方法的關鍵工具。它們被設計為有效且安全的載體，用於傳遞治療基因、糾正基因突變或操縱細胞過程。根據目標細胞、治療基因和所需基因表現持續時間等因素，使用各種類型的病毒作為載體，包括腺相關病毒（AAV）、慢病毒和腺病毒。病毒載體的基因修飾消除或取代致病元件，同時摻入感興趣的治療基因。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 52.2億美元
2028 年市場規模 115.4億美元
2023-2028 年年複合成長率 14.21%
成長最快的細分市場 腺相關病毒載體
最大的市場 北美洲

1. 病毒載體生產的開創性臨床成功：

病毒載體生產的成功臨床應用，其中病毒載體已有效地用於醫學治療和療法，證明了基於病毒載體的方法治療一系列疾病的潛力。例如，Spark Therapeutics 開發的 Luxturna 採用腺相關病毒 (AAV) 載體來治療遺傳性視網膜疾病。 Zolgensma 由 AveXis 開發，使用 AAV9 載體治療脊髓性肌肉萎縮症。這些臨床成功強調了基於病毒載體的療法在治療各種遺傳性和獲得性疾病方面的變革能力。

2.向量工程的進步：

載體工程的進步顯著提高了用於基因治療、基因編輯和疫苗開發的病毒載體的效率、安全性和特異性。對病毒載體的修飾增強了其組織靶向性，降低了免疫原性，並改善了細胞進入以實現有效的基因傳遞。此外，將 CRISPR-Cas9 等基因組編輯技術整合到病毒載體平台中可以實現精確的基因修飾。也正在探索從頭開始設計的合成載體以用於客製化應用。

3. 病毒載體生產中不斷發展的生物反應器技術：

生物反應器技術在生產用於基因治療和基因編輯的病毒載體方面發揮著至關重要的作用。生物反應器為細胞培養、轉染和載體生產提供受控環境，確保一致的品質和產量。拋棄式生物反應器因其易於使用和降低污染風險而受到關注。這些系統提高了可擴展性、產量和質量，同時減少了資源消耗和浪費。

主要市場挑戰

1. 可擴展性和商業化：

從小規模實驗室生產過渡到大規模商業化生產對病毒載體生產提出了挑戰。在維持產品品質的同時擴大生產步驟需要最佳化細胞培養、轉染、純化和品質控制流程。設計符合監管標準的製造設施是資本密集的，與維持高生產力和產品完整性相關的挑戰可能會導致商業化時間延長。

2. 商品成本與定價：

病毒載體生產的專業性以及品質控制措施和監管合規性導致了更高的生產成本。生產中使用的培養基、生長因子和其他原料可能很昂貴。專業任務需要熟練的專業人員，從而增加了勞動成本。這些因素共同影響基於病毒載體的療法的可負擔性和可近性。

主要市場趨勢

1. 製造製程最佳化：

此領域強調改進和改進病毒載體生產流程，以提高效率、降低成本、提高產量並確保品質穩定。最佳化包括增強下游和上游加工步驟、提高產量和維持產品品質。跨設施的標準化流程可確保一致性、合規性和品質。

2. 細分洞察：

AAV 領域的市場主導地位是由基因療法中對 AAV 載體的需求不斷成長所推動的。下游處理在維持載體品質和產量方面發揮著至關重要的作用，因此在工作流程部分中佔據主導地位。由於遺傳疾病持久解決方案的潛力，基因治療應用領域蓬勃發展。研究機構是主要的最終用戶，展示了對尖端療法的承諾。

3. 區域洞察：

由於政府的大力支持、融資以及基因治療和先進療法的蓬勃發展的研發環境，北美在市場上處於領先地位。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球病毒載體生產市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按載體類型（腺病毒、AAV、慢病毒、逆轉錄病毒等）
    • 按工作流程（上游處理、載體擴增和擴展、載體恢復/收穫、下游處理、純化、填充完成）
    • 按應用（基因和細胞療法開發、疫苗開發、生物製藥和藥物發現、生物醫學研究）
    • 依最終用途產業（製藥和生物製藥公司、研究機構）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美病毒載體生產市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按向量類型
    • 按工作流程
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲病毒載體生產市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按向量類型
    • 按工作流程
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太染料市場展望

  • 市場病毒載體生產及預測
    • 按價值
  • 市佔率及預測
    • 按向量類型
    • 按工作流程
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國病毒載體生產
    • 印度病毒載體生產
    • 韓國病毒載體生產
    • 日本病毒載體生產
    • 澳洲病毒載體生產

第 9 章：南美洲病毒載體生產市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按向量類型
    • 按工作流程
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲病毒載體生產市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按向量類型
    • 按工作流程
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非病毒載體生產
    • 沙烏地阿拉伯病毒載體生產
    • 阿拉伯聯合大公國病毒載體生產

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • Merck kgaa
    • Lonza
    • FUJIFILM Diosynth Biotechnologies USA
    • Cobra Biologics Ltd.
    • Thermofisher Scientific Inc.
    • Waisman Biomanufacturing
    • Genezen Laboratories
    • YPOSKESI
    • Advanced BioScience Laboratories, Inc. (ABL inc.)
    • Novasep Holding sas
    • Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
    • Takara Bio Inc.
    • RegenxBio, Inc.
    • Aldevron LLc.
    • Bluebird Bio Inc.

第 16 章：策略建議

簡介目錄
Product Code: 15912

The Global Viral Vector Production Market recorded a valuation of USD 5.22 Billion in 2022 and is expected to exhibit substantial growth during the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 14.21% and expected to reach USD 11.54 Billion through 2028. Viral vector production entails the creation and manufacturing of modified viruses, referred to as viral vectors, which are employed to deliver genetic material into target cells for diverse medical and biotechnological applications. These viral vectors are pivotal tools in advanced therapeutic approaches like gene therapy and gene editing. They are designed to be efficient and safe carriers for delivering therapeutic genes, rectifying genetic mutations, or manipulating cellular processes. Various types of viruses are utilized as vectors, including adeno-associated viruses (AAV), lentiviruses, and adenoviruses, based on factors such as target cells, the therapeutic gene, and desired gene expression duration. Genetic modification of viral vectors eliminates or replaces disease-causing elements while incorporating the therapeutic gene of interest.

The escalating triumph and approval of gene therapies for different diseases, such as genetic disorders and certain cancers, have boosted the demand for viral vectors as essential delivery tools for therapeutic genes. The rising prevalence of genetic disorders and diseases with a genetic component has spurred the requirement for targeted and effective treatments. Viral vectors offer a means to transport corrective or therapeutic genes into affected cells, making them a pivotal component in addressing such conditions. Research organizations, academic institutions, pharmaceutical firms, and biotechnology companies are channeling substantial investments into gene therapy research and development. This increased focus on the field is directly propelling the demand for viral vectors and their production.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 5.22 Billion
Market Size 2028USD 11.54 Billion
CAGR 2023-202814.21%
Fastest Growing SegmentAdenoassociated virus vectors
Largest MarketNorth America

1. Pioneering Clinical Success of Viral Vector Production:

The successful clinical applications of viral vector production, where viral vectors have been effectively used in medical treatments and therapies, have demonstrated the potential of viral vector-based approaches to address a spectrum of diseases. For instance, Luxturna, developed by Spark Therapeutics, employs adeno-associated virus (AAV) vectors to treat inherited retinal disease. Zolgensma, developed by AveXis, uses AAV9 vectors to treat spinal muscular atrophy. These clinical successes underscore the transformative capability of viral vector-based therapies in treating various genetic and acquired diseases.

2. Advancements in Vector Engineering:

Advances in vector engineering have significantly improved the efficiency, safety, and specificity of viral vectors used in gene therapy, gene editing, and vaccine development. Modifications to viral vectors enhance their tissue targeting, reduce immunogenicity, and improve cellular entry for efficient gene delivery. Furthermore, integration of genome editing technologies like CRISPR-Cas9 into viral vector platforms allows for precise genetic modifications. Synthetic vectors designed from scratch are also being explored for tailored applications.

3. Growing Bioreactor Technology in Viral Vector Production:

Bioreactor technology plays a crucial role in producing viral vectors for gene therapy and gene editing. Bioreactors provide controlled environments for cell culture, transfection, and vector production, ensuring consistent quality and yield. Single-use bioreactors have gained traction due to their ease of use and reduced contamination risk. These systems enhance scalability, yield, and quality while reducing resource consumption and waste.

Key Market Challenges

1. Scalability and Commercialization:

Transitioning from small-scale laboratory production to large-scale manufacturing for commercialization poses challenges in viral vector production. Scaling up production steps while maintaining product quality requires optimization of cell culture, transfection, purification, and quality control processes. Designing manufacturing facilities that adhere to regulatory standards is capital-intensive, and challenges associated with maintaining high productivity and product integrity can lead to extended timelines for commercialization.

2. Cost of Goods and Pricing:

The specialized nature of viral vector production, along with quality control measures and regulatory compliance, contributes to higher production costs. Culture media, growth factors, and other raw materials used in production can be expensive. Skilled professionals are required for specialized tasks, increasing labor costs. These factors collectively impact the affordability and accessibility of viral vector-based therapies.

Key Market Trends

1. Manufacturing Process Optimization:

The field emphasizes refining and improving viral vector production processes to enhance efficiency, reduce costs, increase yields, and ensure consistent quality. Optimization includes enhancing downstream and upstream processing steps, increasing yield, and maintaining product quality. Standardizing processes across facilities ensures uniformity, regulatory compliance, and quality.

2. Segmental Insights:

The market dominance of the AAV segment is driven by the increasing demand for AAV vectors in gene therapy. Downstream processing dominates the workflow segment due to its crucial role in maintaining vector quality and yield. The gene therapy application segment thrives due to the potential of durable solutions for genetic diseases. Research institutes are the dominant end users, showcasing the commitment to cutting-edge therapies.

3. Regional Insights:

North America leads the market due to robust government support, financing, and a thriving research and development environment for gene therapy and advanced therapeutics.

Key Market Players

  • Merck kgaa
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A
  • Cobra Biologics Ltd.
  • Thermofisher Scientific Inc.
  • Waisman Biomanufacturing
  • Genezen Laboratories
  • YPOSKESI
  • Advanced BioScience Laboratories, Inc. (ABL inc.)
  • Novasep Holding s.a.s.
  • Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
  • Takara Bio Inc.
  • RegenxBio, Inc.
  • Aldevron LLc.
  • Bluebird Bio Inc.

Report Scope:

In this report, the Global Viral Vector Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Viral Vector Production Market, By Vector Type:

  • Adenovirus
  • AAV
  • Lentivirus
  • Retrovirus
  • Others

Viral Vector Production Market, By Workflow:

  • Upstream Processing
  • Vector amplification and expansion
  • Vector recovery/harvesting
  • Downstream Processing
  • Purification
  • Fill finish

Viral Vector Production Market, By Application:

  • Gene and Cell Therapy Development
  • Vaccine Development
  • Biopharmaceutical and Pharmaceutical Discovery
  • Biomedical Research

Viral Vector Production Market, By End User:

  • Pharmaceutical and Biopharmaceutical Companies
  • Research Institutes

Global Viral Vector Production Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector Production Market.

Available Customizations:

  • Global Dyes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Viral Vector Production Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others)
    • 5.2.2. By Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting, Downstream Processing, Purification, Fill finish)
    • 5.2.3. By Application (Gene and Cell Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research)
    • 5.2.4. By End-Use Industry (Pharmaceutical and Biopharmaceutical Companies, Research Institutes)
    • 5.2.5. By Company (2022)
    • 5.2.6. By Region
  • 5.3. Market Map

6. North America Viral Vector Production Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type
    • 6.2.2. By Workflow
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Viral Vector Production Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vector Type
        • 6.3.1.2.2. By Workflow
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Mexico Viral Vector Production Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vector Type
        • 6.3.2.2.2. By Workflow
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Canada Viral Vector Production Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vector Type
        • 6.3.3.2.2. By Workflow
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Viral Vector Production Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type
    • 7.2.2. By Workflow
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Viral Vector Production Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Workflow
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany Viral Vector Production Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Workflow
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Viral Vector Production Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Workflow
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Viral Vector Production Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vector Type
        • 7.3.4.2.2. By Workflow
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Viral Vector Production Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vector Type
        • 7.3.5.2.2. By Workflow
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Dyes Market Outlook

  • 8.1. Market Si Viral Vector Production ze & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type
    • 8.2.2. By Workflow
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Viral Vector Production Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Workflow
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Viral Vector Production Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Workflow
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. South Korea Viral Vector Production Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Workflow
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Japan Viral Vector Production Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Workflow
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Viral Vector Production Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Workflow
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Viral Vector Production Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type
    • 9.2.2. By Workflow
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Viral Vector Production Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Workflow
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Viral Vector Production Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Workflow
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Viral Vector Production Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Workflow
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Viral Vector Production Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type
    • 10.2.2. By Workflow
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Viral Vector Production Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Workflow
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Viral Vector Production Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Workflow
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Viral Vector Production Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Workflow
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. Merck kgaa
    • 15.6.2. Lonza
    • 15.6.3. FUJIFILM Diosynth Biotechnologies U.S.A
    • 15.6.4. Cobra Biologics Ltd.
    • 15.6.5. Thermofisher Scientific Inc.
    • 15.6.6. Waisman Biomanufacturing
    • 15.6.7. Genezen Laboratories
    • 15.6.8. YPOSKESI
    • 15.6.9. Advanced BioScience Laboratories, Inc. (ABL inc.)
    • 15.6.10. Novasep Holding s.a.s.
    • 15.6.11. Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
    • 15.6.12. Takara Bio Inc.
    • 15.6.13. RegenxBio, Inc.
    • 15.6.14. Aldevron LLc.
    • 15.6.15. Bluebird Bio Inc.

16. Strategic Recommendations